Physician profile
Rachel C Fields
NPI 1063923415
$2,750.21
in general payments reported to CMS, 2019-2025
26 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $158 · 2023: $242 · 2024: $1,097 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $327.90 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $314.09 | 2022-2025 | |
| Pfizer INC. | $257.75 | 2023-2025 | |
| Exeltis, USA INC. | $238.43 | 2023-2025 | Slynd |
| Lundbeck LLC | $224.94 | 2023-2025 | Vyepti |
| Mayne Pharma Commercial LLC | $215.23 | 2023-2025 | |
| Astellas Pharma US INC | $175.75 | 2024-2025 | Veozah |
| Novo Nordisk INC | $141.12 | 2023-2025 | Wegovy |
| Shield Therapeutics INC | $121.14 | 2023-2025 | Accrufer |
| Agile Therapeutics, INC. | $117.42 | 2021 | |
| Millicent US INC | $114.19 | 2025 | Intrarosa, Femlyv |
| Axonics, INC. | $68.11 | 2023-2024 | Bulkamid, Axonics |
| Boston Scientific Corporation | $59.61 | 2024-2025 | General - Female Sui, Solyx Sis System |
| Organon LLC | $58.98 | 2023-2024 | Nexplanon |
| Daiichi Sankyo INC. | $47.44 | 2024 | Injectafer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $44.77 | 2025 | |
| Medtronic, INC. | $43.67 | 2024 | Interstim |
| Sage Therapeutics, LLC | $39.49 | 2024 | |
| Baxter Healthcare | $27.22 | 2025 | Perclot |
| Coloplast Corp | $19.43 | 2023 | Restorelle |
| Bayer Healthcare Pharmaceuticals INC. | $17.01 | 2025 | |
| Lilly USA, LLC | $16.99 | 2024 | Zepbound |
| Exact Sciences Corporation | $15.84 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.84 | 2024 | Quviviq |
| Hologic Sales and Service, LLC | $14.82 | 2025 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.